Urgent

Active pulmonary tuberculosis — treatment

drug-sensitive TB · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pulmonary TB is treated with combination antimycobacterial therapy to cure disease and prevent resistance and transmission. Standard drug-sensitive disease uses a 2-month intensive and 4-month continuation phase, with attention to infection control, adherence and drug toxicity.

Red flags

  • Rifampicin resistance on molecular testing (treat as drug-resistant TB)
  • Massive haemoptysis
  • Drug-induced hepatitis (nausea, jaundice, transaminitis)
  • Visual disturbance (ethambutol toxicity)
  • Miliary spread or TB meningitis

Assessment

Differential diagnosis

  • Community-acquired/necrotising pneumonia
  • Lung cancer
  • Non-tuberculous mycobacterial disease
  • Fungal infection (aspergilloma, histoplasmosis)
  • Sarcoidosis
  • Vasculitis

Investigations

  • Sputum smear microscopy, culture and rapid molecular testing (e.g. Xpert MTB/RIF) with rifampicin-resistance detection
  • Chest X-ray / CT (upper-lobe cavitation, infiltrates)
  • Drug-susceptibility testing
  • HIV test, baseline LFTs, renal function, visual acuity/colour vision
  • Contact tracing and screening

Management

  • Confirm diagnosis with molecular testing and culture, and detect rifampicin resistance early
  • Implement airborne infection control and notify public health
  • Test for HIV and assess comorbidities and baseline organ function
  • Start standard four-drug intensive-phase therapy (RIPE) while awaiting full susceptibilities
  • Give pyridoxine with isoniazid to prevent neuropathy
  • Support adherence (directly observed or video-observed therapy where indicated)
  • Monitor clinical response and convert to two-drug continuation phase after the intensive phase
  • Monitor for hepatotoxicity, visual changes and drug interactions throughout
  • Repeat sputum to confirm culture conversion and guide duration
  • Extend therapy for cavitary/slow-responding disease and manage any resistance via specialist pathways

Drugs & doses

Intensive phase (2 months): Isoniazid 5 mg/kg (max 300 mg) + Rifampicin 10 mg/kg (max 600 mg) + Pyrazinamide 25 mg/kg + Ethambutol 15 mg/kg, all PO once daily
Continuation phase (4 months): Isoniazid + Rifampicin once daily
Pyridoxine 25 mg PO once daily
Fixed-dose combination tablets dosed by weight band

Disposition

Notify public health; TB specialist service; isolation for smear-positive disease; directly/video-observed therapy where adherence is a concern.

Complications & pitfalls

  • Drug-induced hepatitis
  • Acquired drug resistance from non-adherence
  • Haemoptysis / aspergilloma in residual cavities
  • Respiratory failure and bronchiectasis
  • Paradoxical reaction / IRIS in HIV co-infection

Exam pearls

  • Never add a single drug to a failing regimen — it amplifies resistance
  • Rifampicin turns secretions orange and strongly induces hepatic enzymes (contraception, warfarin, ARVs)
  • Monitor for ethambutol-related optic neuritis with baseline and periodic vision checks
  • In HIV, time antiretroviral initiation to balance TB therapy and IRIS risk

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.